Probitas Pharma, the bio-pharmaceutical group, is planning to raise up to €500m ($593m) at its Madrid initial public offering this summer, taking the Spanish pipeline to nearly €2bn.

A spokeswoman for Probitas Pharma said the group was planning an initial offer worth between €400m and €500m but added that the company was still in the process of selecting banks.